- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00548652
Role of Apathy in the Effectiveness of Weight Loss Interventions
Role of Apathy in the Effectiveness of Weight Loss Interventions in Obese Patients
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Title: The role of Apathy in the effectiveness of weight loss interventions in obese patients
Objective: Obesity is a major public health problem. Apathy is a common behavioral problem characterized by loss of initiative, poor motivation and persistence. Presence of apathy impairs the self-care behavior in obese patients. Lack of novelty might impair a patient's ability to seek new interactions, life styles and new treatment options for obesity. Lack of motivation might impair a patient's ability to initiate exercise regimen or diet whereas lack of persistence impairs the compliance with these regimens. Thus, apathy influences all stages of self-care. We hypothesize that the treatment of apathy will result in better adherence to weight loss interventions in obese veterans enrolled in the MOVE program.
Research Design: A prospective open label randomized study. Group 1 will have patients with obesity as defined as BMI>30, and apathy defined as AES score of > 40. This group will be treated with standard nutrition counseling. Group 2 will have patients with obesity and apathy as defined above and will receive the MOVE enhancement program alone (The MOVE program is a national VA weight loss program). Group 3 will be treated with methylphenidate along with the MOVE enhancement program. Group 4 will be treated with medical crisis counseling along with the MOVE enhancement program. Group 5 will be treated with methylphenidate, and the medical crisis counseling along with the MOVE enhancement program.
Methodology: 30 patients meeting the criteria will be enrolled in each of the five arms. All patients will be in the study for duration of six months. All patients in the methylphenidate arm will be started at 5mg twice daily and titrated to 10mg twice daily at two weeks. Patients will be assessed on regular intervals using the Apathy Evaluation Scale, Hamilton Depression Scale and the Patient activation measure. MOVE sessions will be held once weekly from the 2nd visit to the end of the study. Medical Crisis Counseling visits will be every week for nine sessions and then every other week till the end of the study
Clinical Relationships/Significance: The prevalence of obesity in the general population is over 30%. However the prevalence of obesity in the VA health system is almost 70%. Since obesity predisposes to several co-morbid conditions such as hypertension, diabetes and cardiovascular disease, it is important to develop interventions that are effective in inducing weight loss. Since apathy plays a large role in the self care behaviours that lead to obesity, treating apathy may improve adherence to weight loss programs
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Nebraska
-
Omaha, Nebraska, Verenigde Staten, 68105-1873
- VA Medical Center, Omaha
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- BMI >30
- Apathy score >40
Exclusion Criteria:
- History of cancer, except basal cell
- Cardiovascular event in last 6 months
- Renal failure
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Geen tussenkomst: 1
standard nutrition counselling
|
|
Experimenteel: 2
MOVE -weight loss intervention
|
is a VA based multidesciplinary weight loss intervention
|
Experimenteel: 3
MOVE plus medical crisis counselling
|
is a VA based multidesciplinary weight loss intervention
group counselling sessions
|
Experimenteel: 4
MOVE plus methylphenidate
|
is a VA based multidesciplinary weight loss intervention
methyphenidate will be used to treat apathy dose 10mg bid
|
Experimenteel: 5
MOVE plus methyphenidate plus medical crisis counselling
|
is a VA based multidesciplinary weight loss intervention
group counselling sessions
methyphenidate will be used to treat apathy dose 10mg bid
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Apathy Evaluation Scale
Tijdsspanne: 6 months
|
Apathy Evaluation Scale (AES) measures apathy over the previous four weeks Scale range: 18 (minimum score)- 72 (Maximum score) Higher scores indicate higher apathy Better outcome would be reduction in the score
|
6 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Change in Weight
Tijdsspanne: 6 months
|
value at 6 months minus value at baseline
|
6 months
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Cyrus DeSouza, MD, VA Medical Center, Omaha
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 00469
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op MOVE
-
University GhentResearch Foundation Flanders; Agentschap Zorg en Gezondheid, Belgium; Vlaams Instituut...VoltooidDepressieve symptomen | Welzijn | Levensstijl, Gezond | WeerstandBelgië
-
Merck Sharp & Dohme LLCVoltooidLeverfunctiestoornisVerenigde Staten
-
Merck Sharp & Dohme LLCVoltooidNierfunctiestoornisVerenigde Staten
-
Johns Hopkins Bloomberg School of Public HealthAminu Kano Teaching Hospital; Postgraduate Institute of Medical Education and...Voltooid
-
National Cancer Institute (NCI)VoltooidEierstokkankerVerenigde Staten